Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mesocorticolimbic dopaminergic innervation modulates Levodopa-related improvements in gait in older slow walking Adults: A [<sup>11</sup>C]PE2I PET study.

Clinical parkinsonism & related disorders·2025
Same author

Contribution of neuropsychiatric symptoms in Parkinson's disease to different domains of caregiver burden.

Journal of neurology·2021
Same author

Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder.

NPJ Parkinson's disease·2019
Same author

Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease.

European journal of neurology·2018
Same author

Portable objective assessment of upper extremity motor function in Parkinson's disease.

Parkinsonism & related disorders·2017
Same author

Primary treatment of comminuted intertrochanteric fractures of the hip with a Leinbach prosthesis.

International orthopaedics·2016
Same journal

Glutamate-Glutamine metabolism and transport, implications in Parkinson's disease.

International review of neurobiology·2026
Same journal

Redox bioenergetics of neuronal senescence in Alzheimer's disease.

International review of neurobiology·2026
Same journal

Neurovascular coupling and energy substrate delivery in Alzheimer's disease.

International review of neurobiology·2026
Same journal

From metals to mitochondria: Linking trace elements to energy crisis in Alzheimer's disease.

International review of neurobiology·2026
Same journal

Invisible threats of microplastics induced toxicity: Oxidative and inflammatory pathways in the CNS and retina.

International review of neurobiology·2026
Same journal

Starved synapses: Gut microbiome dysbiosis and its role in Alzheimer's glucose impairment.

International review of neurobiology·2026
See all related articles

Related Experiment Video

Updated: May 28, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

Rasagiline in Parkinson's disease.

L M Chahine1, M B Stern

  • 1Penn Comprehensive Neuroscience Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

International Review of Neurobiology
|October 6, 2011
PubMed
Summary
This summary is machine-generated.

Monoamine oxidase (MAO) inhibitors, like rasagiline, are crucial for Parkinson's disease (PD) management. Rasagiline offers neuroprotection and therapeutic benefits, though its disease-modifying potential is debated.

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Related Experiment Videos

Last Updated: May 28, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Area of Science:

  • Neuroscience
  • Pharmacology
  • Movement Disorders

Background:

  • Monoamine oxidase (MAO) inhibitors are established treatments for Parkinson's disease (PD).
  • Rasagiline, an MAO-B inhibitor, exhibits neuroprotective properties in preclinical models, linked to antiapoptotic mechanisms.

Purpose of the Study:

  • To review the role and efficacy of rasagiline in Parkinson's disease management.
  • To discuss the evidence for rasagiline's neuroprotective and potential disease-modifying effects.

Main Methods:

  • Review of clinical trials and preclinical studies on rasagiline in Parkinson's disease.
  • Analysis of rasagiline's efficacy as monotherapy and adjunct therapy.
  • Evaluation of safety and tolerability data.

Main Results:

  • Rasagiline demonstrates efficacy in early PD monotherapy and as an adjunct to dopaminergic treatments.
  • Neuroprotective effects, including antiapoptotic activity, are observed in animal models.
  • Clinical trials suggest potential disease-modifying effects, although this remains a subject of ongoing research and debate.

Conclusions:

  • Rasagiline provides significant benefits for Parkinson's disease patients.
  • Its established efficacy, safety, and tolerability profile solidify its important role in PD therapeutic strategies.
  • Further research is warranted to definitively establish rasagiline's disease-modifying capabilities in Parkinson's disease.